eResearchTechnology, a provider of health outcomes research services to biopharmaceutical sponsors and contract research organizations, announced today that the acquisition of the company by Genstar Capital has been approved.
eResearchTechnology (ERT) is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and contract research organizations to achieve their drug development and healthcare objectives. ERT collects, analyzes, and reports on clinical data to support the determination of health outcomes critical to the approval, labeling and reimbursement of pharmaceutical products. The company is based in Philadelphia, PA (www.ert.com).
Genstar Capital invests in middle-market companies and builds value in those businesses by utilizing the expertise of its operating partners. Genstar has more than $3 billion of committed capital under management and targets investments within the life sciences, healthcare services, financial & business services, software & software services and industrial technology industries. The firm was founded in 1988 and is based in San Francisco, CA (www.gencap.com).
Credit Suisse Securities is acting as the financial advisor to Genstar and Latham & Watkins is acting as legal advisor.